Figure 2.

Declining rates of sudden cardiac death in heart failure trials. The black line reflects the unadjusted rates of sudden cardiac death. The blue line is based on the linear regression of the annualized rate of sudden cardiac death in each trial group with the randomization year and group as covariates.⁹ BEST, Beta-Blocker Evaluation of Survival Trial; CHARM, Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity; CIBIS-II, Cardiac Insufficiency Bisoprolol Study II; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca Heart Failure Trial; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; PARADIGM-HF, Prospective Comparison of Angiotensin-Neprilysin Inhibition with ACE Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure; RALES, Randomized Aldactone Evaluation Study; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial; Val-HeFT, Valsartan Heart Failure Trial.